Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 4 November 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 240,961 of its own shares in the period 27 October – 31 October 2025 at an average price of €44.06. The total consideration of this repurchase was €10,616,126. The total number of shares repurchased under this program to date is 688,969 s...
                                                                                We cut our 2025-28F EPS by 4-5% and target price by 5% to €223 on weaker TVH, PHE and Belron as well as lower multiples, in particular at TVH. We still expect 13% FCFev CAGR 2025-28F and 14% EPS CAGR, on 7% EBIT CAGR. The stock has underperformed 17% since 1H25 and is flat YTD, trading at >40% discount, 11x P/E 2026F, 7% FCFev yield. We remain believers in the long-term story, self-help potential (Belron price/mix, cash/commercial markets, mobile static recalibration, TVH turnaround) but admit t...
                                            ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value27-Oct-25 39,856 €907.51 €36,169,766 28-Oct-25 39,890 €906.74 €36,169,942 29-Oct-25 39,349 €919.20 €36,169,404 30-Oct-25 38,889 €930.08 €36,170,029 31-Oct-25 39,045 €926.37 €36,170,085 ASML’s current share buyback program was announced on 10 Nove...
                                            IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Found...
                                            IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et l'un des principaux fournisseurs de solutions de dosimétrie et d'assurance qualité en radiothérapie et en imagerie médicale (QA), annonce aujourd'hui l'acquisition de PhantomX GmbH, élargis...
                                                                                Arcadis: Feedback from conference call 3Q25. Belgian telcos: Telenet positive net adds in broadband, near ECM decision. CTP: 34k sqm lease signed in Poland. Eurocommercial Properties: Organic momentum is getting stronger. Fugro: Reasonable 3Q, challenging 4Q and beyond. Heijmans: Order book quality improves further. KPN: VodafoneZiggo guidance maintained, ECM decision near. Proximus: CPaaS peer Twilio reports strong 3Q25 results. Retail Estates: Jysk new tenant of 5 Leen Bakker B...
                                                                                This morning Arcadis reported numbers (as written in our FRN) which were at P&L level roughly inline with our forecasts but below consensus. FCF was weak at €80m down from €134m in 4Q25 linked to timing of billing milestones and issues linked with the implementation of Oracle at the 2023 IBI acquisition. Before opening we downgraded to Hold (from Accumulate) as the stock rallied considerably since the announcement of a €175m SBB early October. On top we saw no room for outperformance on our numb...
                                                                                AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
                                                                                Arcadis' 3Q25 trading update was broadly in line. Revenues were up organically by 1% (-4.3% FX impact) and landed at €936m (vs. our €939m (+1.2%) and CSS of € 962m (+1.6%)). Operating EBITA stood at €108m in line with our €110m estimate and slightly below €112m CSS. Posted margins are up 20bps in spite of limited revenue growth. Some €7m non operating costs hit the P&L linked to further restructurings in the UK & Australia. BtB of 0.94x (from 1.3x 3Q24) and BL of €3544m up 1.6% y/y org. but down...
                                            Arcadis Q3 2025 Trading Update: Return to growth, continued margin expansion PRESS RELEASE Arcadis Third Quarter 2025 Trading UpdateReturn to growth, continued margin expansion Net Revenues of €936 million, return to organic growth1): 1.0% year-on-yearOrder Intake of €882 million, resulting in backlog of €3.5 billion with 1.6% organic growth1) year-on-yearOperating EBITA Margin2) expanded to 11.6% (Q3’24: 11.4%), investments in line with strategyContinued portfolio shift towards high growth solutions for energy, water, climate and technology clientsSales process enhancement underway to str...
                                                                                As a follow up to our cheat sheet summarizing the cost structure of a 1GW datacenter, we estimate today on a single slide WFE required to produce semiconductors for a 1 GW datacenter, with our usual important caveat: WFE spending is driven by the growth of production capacity. In other words, one spends once on WFE to build a 1GW datacenter many times over.
                                                                                Hyloris announced that it has entered into an exclusive license and supply agreement with Orion for Tranexamic Acid Intravenous Premix RTU (TXA RTU) in major European markets. This follows a previously announced agreement with Avenacy in the US, though we note this product, being a generic, is non-core for the company, as Hyloris' main focus is on reformulation and repurposing via the 505(b)(2) pathway. The company has not disclosed specific figures under the agreement, however it will be eligib...
                                            Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 28 October 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 61,852 of its own shares in the period 20 October – 24 October 2025 at an average price of €49.22. The total consideration of this repurchase was €3,044,387. The total number of shares repurchased under this program to date is 448,008 sha...
    
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.